In hepatocellular carcinoma (HCC) invasive cell lines, in vitro and in vivo resistance to Sorafenib is caused by the distribution of hepatocyte growth factor (HGF), with the assistance of T-EVs and the subsequent activation of the HGF/c-MET/PI3K/AKT signalling pathway [55]. Here, MET is linked to hepatocellular carcinoma.